CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
Jennifer Gao(United States Food and Drug Administration), Tatiana M. Prowell(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University), Gideon M. Blumenthal(Merck & Co., Inc., Rahway, NJ, USA (United States)), Harpreet Singh(United States Food and Drug Administration), Joyce Cheng(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Paul G. Kluetz(United States Food and Drug Administration), Laleh Amiri‐Kordestani(United States Food and Drug Administration), Marc R. Theoret(United States Food and Drug Administration), Kirsten B. Goldberg(United States Food and Drug Administration), Suparna Wedam(United States Food and Drug Administration), Jacquelyn Sanchez, Julia A. Beaver(Center for Drug Evaluation and Research), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Erik Bloomquist(Center for Drug Evaluation and Research)
Cited by 299
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k